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Abstract 
 
A stepwise pharmacological treatment is currently recommended for all asthma patients and is 
personalized mainly on disease severity, aiming for the lowest step that controls disease. Thus 
mild intermittent asthma is treated with short acting bronchodilators (step 1). If control is 
inadequate, therapies of increasing power are introduced (steps 2, 3 and 4) whereas oral steroids 
(step 5) are reserved for severe asthma. 
Nevertheless, asthma comprises several related pathologies with similar clinical manifestations 
that result from different underlying mechanisms. Therefore novel biomarkers could lead to 
asthma stratification and thus replace the current stepwise approach.  
Promising biomarkers are sputum eosinophils, serum periostin and exhaled nitric oxide. Periostin 
could differentiate between Th2-high and Th2-Low asthma (Th-2-high patients are more 
responsive to glucocorticoids) and the less-defined asthma types which often present a 
therapeutic challenge. Several other biomarkers, mainly cytokines, leukotrienes and exhaled air 
components, can be quantified in body fluids and exhaled breath and could also be useful for 
asthma stratification.  
 
 
 
 
 
 
 
 
Keywords: asthma, biomarker, inflammatory, periostin, eosinophils, exhaled nitric oxide, 
volatile organic compounds, chitinases, prostaglandins. 
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Introduction 
 
Asthma is a complex, chronic disease characterized by episodes of reversible airflow obstruction, 
manifesting in breathlessness, wheezing and cough, with various degrees of airway 
inflammation, remodelling and bronchial hyperreactivity [1]. Short- and long-acting adrenergic 
β2-agonists (SABA/LABA) and inhaled corticosteroids (ICS) have radically improved the lives 
of many asthma sufferers. Recent years have seen notable progress with regard to the 
mechanisms involved in asthma immunology and multiple trials of biological drugs, designed to 
block signaling molecules deemed to be important in its pathology. On the whole, these have met 
with mixed success, but importantly they provided useful mechanistic insights for post-trial 
analyses, demonstrating that patients receiving such drugs could be divided into distinct groups 
of good and poor responders depending on their pre-trial characteristics. This has strengthened 
the hypothesis that rather than being a single disease, asthma consists of a group of pathologies 
which converge towards similar clinical manifestations [2]. 
 
The current assumption is that asthma could be differentiated into subtypes defined by 
biomarkers that reflect the predominant pathophysiology in the case of individual patients. Thus, 
treatment personalization could be achieved using biomarkers [3]. In this review, we outline the 
most effective strategies for identifying biomarkers in asthma, discuss the current experimental 
and clinical evidence for their predictive accuracy and assess their potential usefulness in a 
clinical setting for guiding targeted therapies for this asthma. 
Pathophysiology of asthma: not just a Th2-driven disorder 
In classic allergic asthma, the first exposure of an organism to an allergen may cause 
sensitization, a process whereby an inhaled allergen contacts its specific pattern recognition 
receptor (PRR) on the surface of the airway epithelial cells (AECs), causing them to release 
interleukin-1 (IL-1) [4]. IL-1 is an autocrine mediator, triggering the release of further cytokines: 
granulocyte-macrophage colony-stimulating  factor (GM-CSF), IL-33 [5] and IL-25 [6]. These 
mediators, in turn, activate dendritic cells (DCs) and recently discovered [6] group 2 innate 
lymphoid cells (ILCs) [4]. Subsequently, DCs induce maturation of naive T-cells in lymph nodes 
into T-helper 2 cells, which produce IL-5, IL-9 and IL-13 (Th-2 type cytokines); whereas 
allergen-activated ILCs are able to directly produce these three cytokines [7]. In a simplified 
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description, Th-2 responses can be thought of as B-cell-mediated (humoral immunity), in 
contrast to Th-1 (T-cell mediated, cellular immunity) responses. In healthy humans, precarious 
balance exists between Th-1 and Th-2 responses - excessive activity of the former pathways 
traditionally linked to autoimmune diseases such as multiple sclerosis, while the latter to asthma 
and allergies. 
When re-exposure to the allergen occurs, AECs vigorously resume the production of their ILC-
stimulating cytokines, while DCs vastly upregulate their capacity to promote Th-2 cell 
maturation. Both of these result in a rapid increase in the Th-2 cytokine levels, leading to a 
substantial increase in the airway populations of mast cells, eosinophils and Th-2 cells 
themselves, as well as enhanced B-cell IgE class switching [4]. 
Mast cells are resident tissue cells which play a significant role in sensitization and subsequent 
allergic response. First encounter with an allergen leads to production of IgE antibodies against it 
through Th-2 pathways. These antibodies attach to mast cells through FCεRI receptor. On 
subsequent exposure, antigen molecules bind to the surface-bound IgE molecules, crosslinking 
them and leading to FCεRI activation, induction of complex phosphorylation cascades and mast 
cell degranulation [8], which involves liberation of various pre-formed mediators (histamine, 
serotonin, tryptases). At the same time, there is an upregulation in biosynthesis of freshly 
produced mediators: lipids such as PGD2 and LTC4, and chemotactic factors IL-4, IL-5, IL-6 
[9], leading to inflammatory cell influx and tissue remodelling. MC degranulation can also occur 
in other ways than antigen binding to its IgE, making MC biology much more complex. For 
instance, mast cells possess some receptors for IgG antibodies, and a recent study demonstrated 
that anaphylaxis to peanuts in mice is at least partly mediated by IgG signaling pathways [10]. 
MCs can also be directly activated by various molecules, such as previously mentioned IL-33 
[11]. Basophils are morphologically and functionally similar to mast cells [4]. 
The functions of eosinophils in normal physiology are controversial, with some authors even 
suggesting they are entirely dispensable [12]. Despite the early observation that many asthmatic 
patients have high levels of these cells in their airways, their role in asthma remains largely 
shrouded in mystery. Once perceived simply as end-stage cells recruited by Th-2 cytokines and 
responsible for airway remodeling, they are now thought to be at least partly responsible for Th-2 
cell maturation through IL-4 release [13]. 
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Taken together, asthma could be viewed a disease where AECs and innate immune cells 
cooperate to activate adaptive immune cells in form of Th-2 cells, whose cytokines bring about 
the typically seen pathophysiological changes. However, it has been known for some time that 
many asthma patients do not conform to this simplified view. For instance, Woodruff et al. in 
2009 found that nearly half of the asthmatic patients do not differ from non-asthmatic controls 
with regard to their Th-2 cytokine levels [32]. This can be partly explained by the yet unknown 
functions of the innate immune cells, especially neutrophils, which feature prominently in the 
airways of some patients with severe asthma [14]. Novel T-cell subsets have also been 
discovered, including Th17, Th9, CD8+, TReg, NKT and T cells, each with their likely role in 
asthma [7). Unfortunately, specific immune cell populations investigated in mice (on which the 
majority of research is carried out) can be difficult to translate to humans. Nevertheless, complex 
interactions between immune cells likely explain the diversity of asthma; the next section 
explains the clinical significance of this diversity. 
 
Asthma phenotypes, endotypes and the quest for biomarkers 
 
To date, asthma has been treated using the ‘one size fits all’ approach, i.e. prescribing medication 
to control asthma symptoms, without examining the underlying pathophysiology responsible. 
This has allowed to drastically increase the quality of life of most patients, but important issues 
such as optimal treatment of exacerbations and stepping down the medication remain unsolved      
(for detailed discussion of which we recommend a thorough review by Busse et al. [15]). 
Commonly used ICS have a dampening effect on a broad spectrum of immune pathways and are 
characterized by mild side effects, but are ineffective in some patients, leading to persistent 
asthma symptoms or asthma exacerbations. When this happens, clinicians step up the dose or 
prescribe oral corticosteroids, which possess multiple side effects and hence can only be used for 
short periods of time. However, the increased knowledge of immunology of asthma (see 
previous paragraph) has brought about the realization that asthma constitutes a syndrome or 
group of diseases, sometimes with markedly different pathologies, which often misleadingly 
present with deceptively similar symptoms. Pathological pathways which predominate in one 
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patient may be completely silent in another. Learning how to assess the biochemical pathways in 
asthma in individual patients and introducing drugs able to selectively modify them would 
enable clinicians to personalize asthma therapy [15]. 
In order to better classify heterogenous diseases, we can subdivide them into ‘phenotypes’, 
which are sets of easily measurable characteristics, such as patient symptoms or clinical 
measurements. Crucially, knowledge of phenotypes does not require the knowledge of the 
underlying pathophysiology, relying instead on purely statistical methods, such as cluster 
analyses (methods for dividing subjects/objects into distinct sets with similar characteristics). 
‘Endotypes’ can be thought of as subtypes of diseases assigned on the basis of elucidated 
pathophysiology. As such, endotypes are more objective and potentially more useful, and would 
reflect a higher level of understanding of asthma, which has not yet been achieved – current 
approaches rely on identifying phenotypes. Various cluster analyses have been performed to 
distinguish phenotypes, such as that by Moore et al. in 2010, who divided 726 patients into 5 
distinct asthma phenotypes [16]. Having analysed a number of similar studies, Wenzel in 2012 
divided the known asthma phenotypes into two main groups: Th-2 and non-Th-2 asthma [17]. 
The former category encompasses classical inflammatory asthma phenotypes, which are 
amenable to treatment with ICS, such as childhood allergic asthma. The latter contains more 
mysterious phenotypes such as obesity-associated asthma and neutrophilic asthma, which often 
arise in adults and are frequently resistant to standard treatment. It is hoped that better 
understanding of these phenotypes and ultimately elucidating their pathophysiology would help 
design selective, targeted treatment which could be given to the patients suffering from the 
particular phenotype, in place of the current stepwise treatment strategy. 
 
The identification of asthma phenotypes necessitates the use of biomarkers whose ideal features 
are the following: 
1) High sensitivity and specificity (and the associated positive and negative predictive 
values), allowing to reliably identify a given phenotype and exclude other phenotypes.  
2) Easily measurable, not requiring complex, expensive and potentially risky interventions. 
Page 5 of 37
URL: http://mc.manuscriptcentral.com/ero   Email: Claire.Raison@informa.com
Expert Review of Molecular Diagnostics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
6 
 
3) Correlated with treatment responses, e.g. allowing treatment adjustments on the basis of 
observed trends in biomarker values. 
4) Biomarkers should be useful to better understand the underlying asthma pathology 
(phenotypes could then be replaced by endotypes). 
5) Finally, an ideal biomarker should provide quick and direct results to facilitate its clinical 
use. 
Below we discuss the key asthma biomarkers and evaluate which phenotypes they are likely to 
distinguish between. 
 
Airway biopsies, bronchoalveolar lavage and sputum leukocytes 
Airway biopsies provide a good indication of asthma severity, allowing physicians to determine 
the extent of tissue remodeling and local inflammation. However, their inherent invasiveness and 
considerable cost limit their application to the most complicated, treatment-refractory asthmatic 
patients. Bronchoalveolar lavage (BAL) is slightly less cumbersome, but still needs to be 
performed in a hospital, which restricts its widespread use. In contrast, assessment of induced 
sputum is less invasive and more cost effective – although still too awkward for routine use [3]. 
Sputum cellularity is important in order to detect the percentages of neutrophils and eosinophils 
which are strongly implicated in airway inflammation at all levels of asthma severity.  
Simpson et al. in 2006 investigated induced sputum samples of 93 non-smoking asthmatic 
patients and 42 controls [18]. The aim was to investigate the best way of diagnosing non-TH2 
asthma (which they named NEA, non-eosinophilic asthma) based on sputum cell counts and its 
variability between patients. For that purpose, they obtained induced sputum samples and 
quantified the neutrophil and eosinophil levels within these. 
The authors found that calculating both absolute and relative levels of sputum eosinophils 
yielded similar results, allowing them to establish four asthma phenotypes: eosinophilic (raised 
eosinophil levels), neutrophilic (raised neutrophil levels), mixed granulocytic (raised neutrophils 
and eosinophils) and paucigranulocytic (normal neutrophil and eosinophil levels). Moreover, 17 
out of 18 asthma patients who were originally classed as NEA at the beginning of study retained 
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their allocation to that group after 4 weeks and 6 out of 7 NEA classified patients who attended a 
follow up visit approximately 5 years after the original study still maintained their status. 
Interestingly, the study did not find any significant clinical differences between the patients, 
except for a higher mean age in the neutrophilic asthma group. This study aimed to achieve 
asthma stratification as it was one of the first to measure multiple indices in relation with induced 
sputum eosinophils and neutrophils which are known to be effectors in asthma pathogenesis. 
Whether these induced sputum biomarkers will be useful for personalizing asthma treatment is 
however still unclear. Various trials have demonstrated that sputum eosinophils and neutrophils 
may be used to guide ICS dosing to reduce the frequency of and predict asthma exacerbations 
and to indicate asthma severity. 
Possibly the most important study in this field was one by Green et al. in 2002 [19]. The authors 
randomized 74 asthmatic patients to either sputum management group, where management was 
guided by sputum eosinophil concentrations and severity of symptoms, or to British Thoracic 
Society group, with treatment guided by this Society’s asthma guidelines. When the study was 
finished after one year, the authors found that the former group had significantly fewer sputum 
eosinophils (63% lower as measured during 9 visits over 12 months; P = 0.002), and more 
importantly, fewer asthma exacerbations (35 vs 109; P = 0.01) than the latter group. The authors 
surmised that eosinophils have a central role in asthma pathology, including asthma 
exacerbations, and corticosteroids may possibly act by dampening their activity. However, the 
authors did not demonstrate any significant correlation between eosinophils and lung function, 
asthma symptoms, or quality of life. The study was also of small size, and examined a specific 
patient group of severe, refractory asthmatics. A similar study by Chlumsky et al. produced 
strikingly similar results – vastly decreased exacerbation rate with no difference in symptoms or 
lung function [20]. 
In addition, measurement of induced sputum biomarkers needs to be standardized for the results 
to be used in any diagnostic form; and even then, the invasiveness and time needed for this test is 
a significant difficulty.  
In response to this problem, study in 2013 by Hastie et al. endeavored to find whether sputum 
eosinophils and neutrophils could be accurately predicted using less invasive and time 
Page 7 of 37
URL: http://mc.manuscriptcentral.com/ero   Email: Claire.Raison@informa.com
Expert Review of Molecular Diagnostics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
8 
 
consuming biomarker surrogates [21]. The team measured several biomarkers that had 
previously been suggested to be associated with sputum eosinophil and neutrophil counts. These 
biomarkers are currently used but are not validated and have been questioned by other studies 
regarding their power of prediction [22,23,24,25,26]. 
These biomarkers include blood eosinophil counts, exhaled nitric oxide (FeNO) and IgE levels to 
predict sputum eosinophils and age, FEV1 percent predicted and blood neutrophil counts to 
predict sputum neutrophil counts. Hastie et al. found that while these surrogate markers do 
correlate with sputum cell counts but they do not have an accuracy or predictive power much 
above what we may expect by chance [7]. An example of this is blood eosinophils and 
neutrophils, which showed a predictive power of 64-69%. This is likely to be explained through 
biological processes such as cells transmigrating to tissue, which may cause transiently increased 
levels in the blood cell counts and also due to the large variation seen within atopic asthma 
patients. By using the aforementioned surrogate biomarkers they were able to allocate 41% of 
the patients into their correct granulocytic group, however, this again must be improved upon 
before it can be used within any clinical or diagnostic setting. 
Airway remodeling is another cardinal feature of asthma. In 2010 Chakir et al. evaluated the 
influence of sputum eosinophil count-led vs clinical-led management in terms of the extent of 
airway remodeling over a 2 year period  study involving 20 participants. Airway remodeling was 
measured by the expression of mucin 5A (MUC5A) and subepithelial collagen layer thickness 
from bronchial biopsy specimens, collected twice with two year treatment period between 
collections. After two years, mucin staining in sputum-led group was significantly smaller than 
in clinical-led group, and the amount of total eosinophils decreased in sputum-led group, but 
there was no difference between these groups in terms of collagen deposition. This study used a 
small group of patients, but it is interesting to note that the was no difference between sputum-
led and clinician-led management in terms of remodeling, apart from a difference in MUC5A 
expression. This indicates that the role of eosinophils in airway remodeling in asthma is still 
largely mysterious. 
In summary, sputum eosinophils and neutrophils have increased our understanding of asthma 
phenotypes and to date, are good predictors of airway TH2 inflammation and subsequent asthma 
severity, especially when used in conjunction with age of onset and FEV1 predicted values. 
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However, more work is needed to find more efficient and less invasive biomarkers that can 
accurately predict eosinophil and neutrophil levels within a point-of-care setting and then these 
cell counts are likely to become a useful adjunct for confirmation. 
Periostin 
Periostin is a matricellular protein found in numerous tissues. Bornstein et al. in 1995 described 
matricellular proteins as extracellular proteins which fulfill a non-structural, regulatory role by 
binding to the cell surface and structural components of the extracellular matrix, such as 
proteoglycans or collagen [27]. Periostin acts as a ligand for αVβ3 and αVβ5 integrins and 
appears important for cell migration and extracellular matrix remodelling [28]. Apart from its 
physiological role, it has also been found to be crucial in a number of pathological processes, 
including growth and metastasis of multiple cancers [29]. Sidhu et al. proved experimentally in 
2010 that periostin is secreted by airway epithelial cells in response to IL-13, a well-known 
signalling molecule in asthma, and contributes to TGF-β activation and airway remodelling 
through increased collagen synthesis [30]. 
In a study investigating the relevance of periostin for measuring the severity of asthma in 2007 
Woodruff et al. measured gene expression in airway epithelial cells in healthy subjects, asthmatic 
patients (before and after ICS therapy) and smokers [31]. 22 genes in asthmatics not receiving 
corticosteroids were differentially expressed when compared to control patients, although the 
difference for most genes was less than twofold, with only 5 genes expressed at least 3 times 
stronger in asthmatics. These genes were: CLCA1 (chloride channel, Ca
2+
-activated 1; 6.2-fold 
increase), POSTN (periostin; 4.4-fold increase), PRR4 (proline rich 4 {lacrimal}; 3.9-fold), 
SERPINB2 (serine peptidase inhibitor B2; 3.5-fold) and CPA3 (carboxypeptidase A3 {mast 
cell}; 3.3-fold). Here we focus on periostin, as it is supported by comparatively largest body of 
evidence from studies. Treatment with fluticasone decreased periostin expression 2.1-fold, 
although only 27 patients finished this arm of the trial. Unfortunately, these changes were 
calculated from the material biopsied at baseline and one week after the commencement of the 
trial – a potentially insignificant treatment period, even taking into consideration that the 
asthmatics enrolled were required to be steroid-free for at least 4 preceding weeks. A strength of 
the study was that the authors demonstrated that IL-13 increased periostin expression, and 
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showed that periostin could also be suppressed through use of ICS dexamethasone and 
budesonide. This seminal work has been valuable in terms of periostin being identified as a 
potential biomarker for predicting severity and airway remodelling in asthmatics.  
(Table 1) 
Following on from the above study, Woodruff et al. in 2009 conducted an analysis on the same 
samples that had been collected two years before [32]. Their previous study had concluded that 
three genes – POSTN, CLCA1 and SERPINB2 were expressed in a group of asthma patients and 
that their levels might reflect the extent of TH2-related inflammation. In this study, the authors 
performed a simple cluster analysis of 42 asthmatics and 28 controls anddiscovered that in 20 of 
the asthmatics the TH2 inflammatory signature (measured by the expression of the three 
mentioned genes) wasvirtually indistinguishable from that of controls. In other words, 20 
asthmatic patients did not significantly overexpress the three TH2 genes which are related to IL-
13 responses. The authors named these patients ‘TH2-low’ and established that they had 
accordinglylow levels of IL-13 and IL-5. In contrast, the remaining 22 asthmatics had 
significantly higher levels of expression of the three genes and of both cytokines and were 
dubbed ‘TH2-high’. Notably, individual patients exhibited high levels of correlation between the 
three mentioned genes (Spearman’s rank order correlation {ρ} ranging from 0.77 to 0.88 with P 
< 10
-4
), indicating that in future measurement of one of them (e.g. periostin in this case) might be 
sufficient to distinguish between TH2-high and TH2-low asthma. 
 
Furthermore, the latter group had greater airway hyperresponsiveness, circulating IgE and 
eosinophil levels and more extensive airway remodelling than the former group. The researchers 
also found a difference between these groups in response of FEV1 to ICS over 2 weeks of 
treatment: TH2-high individuals had a robust improvement in FEV1 (which returned to baseline 
after discontinuation of therapy), whereas TH2-low patients paradoxically experienced a 
worsening of their airway function. This indicates that IL-13 and IL-5 are suggestive of a more 
severe subtype of asthma, potentially reflected by periostin as biomarker Unfortunately, the 
authors did not mention the exact cutoffs for POSTN, CLCA1 and SERPINB2 which they used 
for stratifying patients into ‘TH2-high’ and ‘TH2-low’ categories. 
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In addition to periostin (possibly together with CLCA1 and SERPINB2) being used to 
distinguish between TH2-high and TH2-low asthma, it will be important to find out in the future 
whether periostin can also be used as a biomarker for more specific classifications of TH2-high 
asthma endotypes. 
Corren et al. in 2011 organized a randomized, double-blind, placebo-controlled, multicentre 
clinical study investigating immunosuppressive treatment of asthma using lebrikizumab (anti-
IL13) [33]. 219 adult patients with suboptimal asthma control, potentially indicating steroid 
resistance, were enrolled while being treated with ICS. The authors assessed patient Th-2 status 
by measuring blood IgE and eosinophil levels; serum periostin was measured later. Patients were 
then randomized to receive lebrikizumab or placebo once monthly for 6 months, and multiple 
assessments were performed during the study. At 12 weeks, the increase in pre-bronchodilator 
FEV1 (from baseline) was significantly larger in lebrikizumab than in placebo group: 9.8% vs. 
4.3%. However, when the patients were stratified according to their pre-treatment periostin level, 
the difference in outcomes was magnified: in high-periostin group, the mean increase in FEV1 
vs. placebo was 14.0% vs. 5.8%, whereas in the low-periostin group, the mean increase in FEV1 
vs. placebo was 5.1% vs. 3.5%. This difference in FEV1 was apparent from week 1 and 
continued until week 32, when the study was terminated. Unfortunately, lebrikizumab did not 
alter asthma symptoms, nor did it diminish the need for the use of rescue medication, although 
there was a non-significant (p = 0.10) decrease in the rate of reported exacerbations. The results 
of this study are somewhat ambiguous – the rise in FEV1 was significant, but there were no 
differences between the antibody and placebo in secondary outcomes, possibly indicating that 
TH2-high asthmatics are more responsive to ICS treatment and that IL-13 may only be one 
effector in the frame of a complex disease.  
Noonan et al. in 2013 performed a similar study with the same medication and primary endpoint 
[34]. Crucially, the patients in this study were well-controlled, and not corticosteroid-resistant 
asthmatics. Of 212 randomized patients, 117 (56%) were classed as periostin-high, and 93 (44%) 
as periostin-low. The authors found slight improvements from baseline FEV1 in periostin-high 
patients (2.3%-4.8% depending on the dose), but deemed them not statistically significant. They 
did however find that lebrikizumab drastically lowered treatment failure as defined by the need 
to commence ICS therapy (27% in placebo group vs. 6% in antibody group). Despite 
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encouraging results, a significant weakness of this study was in the randomization: placebo 
recipients were significantly skewed towards periostin-high status (only 18 low-periostin patients 
received placebo).  
Statistical issues aside, the discrepancy between this and Corren’s study may be explained by the 
population differences: in patients not receiving steroids, multiple pathological pathways may be 
active and hence selective blockade of IL-13 may not be an adequate treatment for some of them. 
In contrast, in the steroid-resistant patients the effect of IL-13 may be more pronounced and 
therefore more amenable to treatment. Regardless of this, it indicates the level of complexity of 
asthma pathophysiology and the need for careful evaluation of the effects of antibodies in 
different patient cohorts. 
A study by Hanania et al. shows a much clearer indication of periostin’s suitability as a 
biomarker [35]. In 2013 they performed a post-factum analysis of their 2011 EXTRA study [36]. 
This trial enrolled a substantial cohort of 850 patients of various ages, all suffering from poorly-
controlled, steroid-resistant, allergic asthma. At the onset of the study, patients were stratified 
according to the current medication used and the levels of three putative TH2 inflammation 
biomarkers were measured in most of the patients throughout the study: exhaled nitric oxide 
(FeNO), peripheral eosinophil count, and serum periostin. The cut-off between periostin-high 
and periostin-low groups was selected as a median measured value of 50 ng/ml. A significant 
advantage of the study was that serum periostin measurements were available from a much 
greater sample of patients (534) than in any of the studies described above.  
The authors found that the use of omalizumab decreased exacerbatio  rates from 0.93 to 0.66 in 
periostin-high group, whereas it had no significant effect in the periostin-low group (0.72 vs. 
0.73). Therefore, the treatment with this antibody decreased exacerbation rates in periostin-high 
group below that of periostin-low group. However, no significant changes were observed in 
FEV1 or asthma symptoms.  
The major disadvantage of periostin at the moment appears to be its limited capability to identify 
more asthma endotypes within the ‘Th2-high’ phenotype. Whilst periostin can differentiate 
between TH2-high and TH2-low asthma, additional use of other biomarkers seems to be 
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necessary in order to detect shed more light on the complex Th2-high asthma. However, a much 
larger sample population with more control over compounding, external factors such as 
medications will need to be examined before any such additional biomarkers can be ascertained.  
 
Exhaled nitric oxide (FeNO) 
Nitric oxide (NO) is a short-lived, gas free radical that acts as a paracrine mediator in many 
tissues. Famously identified as the endothelium-derived relaxing factor (EDRF) by Furchgott, 
Zawadzki and Ignarro [37,38], It subsequently became the founding member of a new family of 
molecules called gasotransmitters – gaseous mediators responsible for a wide variety of 
physiological processes [39].NO is produced from a natural amino acid L-arginine by nitric 
oxide synthase (NOS), which exists in three isoforms [40]. NOS1 (neuronal NOS, nNOS) and 
NOS3 (endothelial NOS, eNOS) depend on calcium ions and are mostly constitutive, whereas 
NOS2 (induced NOS, iNOS) is calcium-independent and instead its activity is usually switched 
on and off by other intracellular signals [41]. It is the latter enzyme that is mostly important for 
NO production in asthma and other inflammatory conditions [42]. When NO was found to be 
measureable in the exhaled air of some asthmatic patients, with a reported 2-3 fold increase from 
baseline when compared to healthy controls [43].,it was  realized that the level of this gas in 
exhaled air (FeNO) might be utilized to assess the extent of airway inflammation in this disease. 
These hopes were fuelled by the low cost, quickness and non-invasiveness of measuring exhaled 
FeNO [44]. However, multiple studies on the clinical utility of FeNO have been published since 
then and the resulting picture is far from clear. This is best demonstrated by the fact that some 
countries, such as United States, have enthusiastically adopted FeNO as an asthma biomarker, 
whereas others, such as UK, have been more cautious in this matter. The body of evidence is 
large, but many studies do not appear to carry much weight due to design problems or 
insufficient size. Therefore, we have focused on the largest, most recent and interesting studies 
or meta-analyses both in adults and children. 
In 2012 Petsky et al. performed a meta-analysis of two adult and four children asthma studies 
investigating a total sample population of 1,053 adults and children and utilizing the FeNO 
biomarker[45]. The authors found that using FeNO values to guide therapy with corticosteroids 
lead to a daily ICS dose decrease by a mean of 450.03 µg budesonideequivalent in adults, but a 
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140.18 µg increase in children. There were no differences in other parameters, most importantly 
the frequency of exacerbations and perceived asthma symptomsOn the whole, this meta-analysis 
does not support the use of FeNO as a useful biomarker for guiding asthma treatment in adults 
and children alike, although one might argue that exacerbations and FeNO cut off values were 
variably defined between the six studies (the latter ranging widely from 20 to 35 ppb) 
It is worth looking separately at the two adult asthma studies included in the above meta-
analysis. Smith et al. in 2005 constructed a single-blind trial with 97 participants, who were 
assigned to have their optimal fluticasone (ICS) doses specified based on either FeNO values, or 
standard clinical algorithms [46]. After the optimal doses were found, the study lasted for 1 year, 
with continued 2-monthly measurements of FeNO and clinical indices in order to titrate the ICS 
dose. The authors found that the only significant difference between the FeNO-led and clinical-
led groups was the mean daily fluticasone dose, with the latter group taking 370 µg of this 
corticosteroid, and the latter 641 µg (P = 0.003). This indicated that patients assessed on the basis 
of their clinical indices might have been overtreated, as supported by an earlier meta-analysis 
demonstrating highest benefit from ICS at the doses up to about 500 µg per day [47]. 
Interestingly, sputum eosinophil counts in both groups were similar and below 3% threshold 
defined as clinically important. However, the study was quite small (97 patients), single-blind 
and importantly did not allow patients to take long-acting beta agonists, an important asthma 
medication. Interestingly, Shaw et al. conducted a similar study in 2007 on 120 patients and 
found that there was no statistically significant difference between both groups in terms of 
cumulative ICS dose used over 12 months, although FeNO-led patients did have a significantly 
lower final ICS dose (557 vs. 895 ug, P = 0.028). As a criticism, this study was also single-blind 
and used severe asthma patients rather than general asthmatic population. It is generally difficult 
to compare such studies due to differences in FeNO targets and in management protocols, 
although general consensus existed at the time that exacerbation rates were not affected by 
management method in any of these studies.(Table 2) 
 
Another study, which failed to find FeNO to be useful as a biomarker was the BASALT study, a 
recent (2012) randomized controlled trial organized by Calhoun et al. [48]. This study was 
similar to the ones included in Petsky’s meta-analysis, aiming to compare FeNO and daily 
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asthma symptoms for the prevention of asthma exacerbations compared to the traditional 
assessment by physician. In this study 342 adults were randomized to three groups, and doses for 
ICS were adjusted based either on the respective FeNO indication of asthma severity, a 
physician’s assessment every 6 weeks or a daily assessment of generic asthma symptoms. 
Notably, biomarker-based dose adjustment was not significantly superior to the clinician’s 
assessment-based adjustment – showing an exacerbation rate of 20% vs. 22%. Daily symptom-
based assessment was marginally better with an exacerbation rate of 15%, but was still deemed 
insignificant by the authors. As the rate of exacerbations was lowest in the last group of patients 
in whom ICS dose was adjusted daily based on symptoms (rather than every six weeks), an 
improvement could have been made by including a fourth cohort of patients in whom FeNO 
measurements were performed daily and ICS dose matched on a daily basis to thus obtained 
FeNO readings. Of course, the use of such strategy would require equipping every patient in the 
cohort with an FeNO meter or require daily visits to their physician to have their FeNO assessed 
over several months. 
From the methodological point of view the above study is also limited in another way – it 
assessed only mild-to-moderate asthmatics, in which the degree of underlying airway 
inflammation is also likely to be only mild to moderate. In contrast, FeNO is postulated to be 
increased in active, severe airway inflammation, so perhaps it is not surprising that it was not 
found to be elevated in the above cohort of patients. The real usefulness of FeNO might lie 
simply in distinguishing between patients with overactive TH2 responses from these without such 
inflammation, similar to periostin.  
The most convincing piece of evidence for such stratifying power of FeNO comes from the 
previously discussed EXTRA study of omalizumab, in which FeNO values obtained from 394 
patients were available for analysis [20]. Although not nearly as significant as periostin results, 
in FeNO-high subgroup of patients, there was a substantial 53% reduction in the exacerbation 
rate, over three times that of FeNO-low subgroup (16%). 
Another important study concerned with discrimination between asthma subtypes is one by 
Amelink et al.[49]. In 2013 they investigated mild-to-moderate and severe adult-onset asthma 
patients, attempting to describe the differences between these two subgroups and determine 
potential markers that would in future allow to distinguish between them more easily. Having 
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stringently excluded all patients with severe co-morbidities or any uncertainties regarding their 
diagnosis, authors recruited 78 patients suffering from severe and 98 suffering from mild-to-
moderate asthma. The authors measured multiple clinical indices during the study, allowing for a 
comprehensive analysis. Predictably, severe-asthma patients had lower quality of life and higher 
degree of overall healthcare utilization. More significantly, they were also characterized by less 
allergy sensitivity (34% vs. 52%), more frequent nasal polyposis (54% vs. 27%) and more 
significant airflow impairment and air trapping compared to their mild-to-moderate counterparts. 
Among the multiple factors correlated with disease severity, authors identified FeNO with a 
significant odds ratio of 1.5. Even though blood neutrophils, nasal polyposis and absence of 
atopy ranked significantly higher as severity-associated factors, it is important to remember that 
FeNO is considerably faster, cheaper and more convenient to measure than any of these 
biomarkers. Sputum eosinophils were also slightly elevated in severe-asthma patients (odds ratio 
of 1.4), which appears consistent, as NO is abundantly produced not only by endothelial, but also 
by the airway inflammatory cells [50]. Therefore, FeNO measurement may be potentially useful 
for distinguishing this adult-onset, severe-asthma phenotype in addition to blood neutrophils and 
sputum eosinophils to improve accuracy. 
Crucially, the above study did not identify obesity or patient gender to be correlated with adult-
onset asthma severity. However, a few authors have described another late-onset phenotype, 
associated with obesity in women, which they claim is different to the neutrophilic phenotype 
described by Amelink’s study. In this phenotype, inflammation is decreased as detectable by 
diminished FeNO values and airway eosinophilia.  
Obesity has a complex relationship to asthma, with higher BMI values predicting worse 
prognosis in this disease. Moreover, the rise in the prevalence of obesity is concurrent with that 
of asthma and allergies. Therefore the relationship between BMI, asthma and inflammation may 
be of some significance. Holguin et al. last year (2013) performed a cross-sectional analysis on a 
population from the Severe Asthma Research Program (SARP) (see References) to test a 
putative mechanism responsible for a decrease in FeNO in overweight and obese patients [51].  
The authors focused on asymmetric dimethylarginine (ADMA), a substance known to interfere 
with nitric oxide synthase (NOS), an enzyme crucial for the production of this gaseous mediator. 
ADMA, same as NO, is produced from a natural amino acid L-arginine and therefore the ratio of 
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L-arginine to ADMA is informative of the efficiency of the formation of this gas. The 
researchers found that patients with late-onset asthma exhibited lower L-arginine/ADMA ratio 
than the patients with early-onset asthma (median of 109 vs. 121). Additionally, the inverse 
correlation of this ratio to BMI was significantly greater in late-onset vs. early-onset patients (r = 
−0.4 vs. r = −0.2). This ratio was found to be correlated with log FeNO (r = 0.39) throughout the 
study population. The authors have also found that in late-onset asthma decrease in L-
arginine/ADMA ratio exacerbates FEV1, but the opposite is observed in early-onset asthma. 
The study by Holguin et al. demonstrated how obesity may result in the induction of late onset 
asthma phenotype. It should be noted here that ADMA is relevant across asthma phenotypes due 
to its inhibition of nitric oxide synthesis. ADMA is prominent in this section as it appears to be a 
significant, putative mediator that could explain the inverse relationship of  BMI to Fe(NO) in 
the late-onset, asthma phenotype. In patients afflicted with this asthma phenotype (mainly obese 
women), uncoupled NOS produces significantly less NO and more reactive oxygen species 
(ROS), which may impair respiratory function. Both reactive oxygen species’ [52] and ADMA 
levels [53] have been demonstrated to be increased in obese individuals, which supports this 
theory. The explanation of the molecular underpinning of this asthma phenotype is also 
particularly attractive due to fact that a deficit in L-arginine is readily corrected with L-citrulline 
and thus may be a useful adjunct to conventional asthma therapy [54]. Importantly, this study 
used a pre-determined cohort from SARP study in which the levels of L-arginine and ADMA 
were measured, and may not necessarily be representative of the general population. This may 
potentially serve as a useful proof of concept and identifies the directions of future research, but 
this needs to be improved upon, using a larger trial in future.Finally, another special population 
of asthmatic patients are smokers, who are more difficult to diagnose and treat with ICS than 
non-smoking patients [55]. From diagnostic point of view, smokers have been reported to have 
decreased FeNO levels, diminishing its potential usefulness as a biomarker in this population of 
patients [56]. To test whether this biomarker could still be used in this population, Spears et al. in 
2011 measured FeNO and performed spirometry in 22 smokers and 21 never-smokers both 
before and after 2 weeks of oral steroid treatment. Obtained values were then mathematically 
analyzed in a novel way to obtain two indices, alveolar nitric oxide (Calv) and nitric oxide flux 
(J’aw). The authors found that while FeNO and two indices were decreased in smokers, J’aw, and 
not FeNO and Calv, was decreased by steroid therapy, potentially raising hopes that J’aw could be 
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used an asthma biomarker in future. Notably, this was a small unblinded study, with all the 
inherent consequences – for instance, no relationship between J
’
aw and ICS dose was found, 
which could be either due to small study size, or weakness of this index as a biomarker. 
Nevertheless, this study is interesting as a proof of concept and provides a foundation for future 
efforts. 
In the above section we have discussed a small fraction of the existing clinical evidence for the 
clinical utility of FeNO as an asthma biomarker. While the clinical utility of this biomarker may 
not been demonstrated as satisfyingly as that of periostin, it holds the two key advantages over 
this substance: one is the ease and low cost of measurement, and another, its potential to identify 
more asthma phenotypes than periostin. It seems that a combination of periostin and FeNO 
would be more informative for guiding asthma therapy than each of these alone. However, more 
data will be necessary to firmly establish their use. 
 
Other biomarkers 
(Table 3) 
Cysteinyl-leukotrienes (Cys-LT) are simple lipids which are known to be important for 
paracrine signaling and the acknowledgment of their participation in asthma pathophysiology has 
culminated in the introduction of leukotriene receptor antagonists (LTRA). These medications 
are characterized by very few side effects, and even though slightly less efficient than long-
acting beta agonists when combined with ICS, they nonetheless have their role in the asthma 
clinic. The discovery that only a small fraction of patients benefit significantly from LTRA, 
coupled with the fact that LTE4 can be readily assayed in the urine, has prompted interest in the 
use of this Cys-LT for predicting therapeutic response to LTRA [1]. 
Cai et al. in 2007 administered montelukast (a Cys-LT receptor antagonist) to 48 mild-to-
moderate asthmatics over a period of 4 weeks, and used strict criteria (improvement of asthma 
symptoms, FEV1 and reduction in SABA use) to classify them as responders or non-responders 
[57]. 25 patients responded to the therapy, and they had a mean LTE4 concentration of 224.5 ± 
34.4 pg/mg creatinine, compared to that of 175.3 ± 37.1 in non-responders. The study used a 
limited number of patients with moderate disease, however, they were able to demonstrate the 
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potential of this biomarker for indicating whether to use montelukast or not. Cai et al. showed 
that patients who measured > 200 pg LTE4/mg creatinine were 3.5 times more likely to respond 
to this drug than patients below this threshold. While the collection of urine is non-invasive, 
assessment of LTE4 level by mass spectrometry requires appropriately trained staff and relatively 
costly equipment, although the prices may be expected to decrease. 
Prostaglandins’ relationship to asthma, specifically allergic asthma, has been investigated over 
the past decades as their connection to mast cells, a major mediator in bronchoconstriction, 
eosinophil trafficking and potentially asthma progression [58,59] has been elucidated [60,61]. 
Specifically, prostaglandin E2 (PGE2) has been linked to mast cell degranulation inhibition and 
subsequent reduction in bronchoconstriction. Sastre et al. in 2008 showed that asthmatics have a 
reduced level of PGE2 [62], which may be linked to inhibition through mast cell activation, as 
recent studies have suggested that the observed reduction in PGE2 may be a contributor in 
asthma progression [63]. 
This prostaglandin can be easily measured in urine and given more research into its predictive 
power and whether the beneficial effects of PGE2 as a muscle relaxant in asthma are 
physiologically linked to its inhibitory effects on mast cells, may prove to be a beneficial 
biomarker, or adjunct to, for stratification and guided treatment in allergic asthma. 
Volatile organic compounds (VOC) can be measured in the exhaled air, and their profiles could 
be used to diagnose and distinguish between asthma and COPD and, to a certain degree, give an 
indication of asthma severity.  
Multiple substances have been reported to be elevated in the air exhaled by asthmatics, including 
pH, isoprostanes (widely used in cardiovascular and respiratory research as markers of oxidative 
stress) and adenosine [3]. These VOCs are practically utilised to form breath profiles or prints, 
which can be indicative of airway inflammation using a technology termed the ‘electronic nose’ 
that is part of a novel but growing technology group called smell analysis. 
Electronic nose technology is being studied extensively in asthma for its specificity and 
sensitivity in detection and discrimination of airway inflammation. Fens et al. showed in 2011 
that the electronic nose had a sensitivity and specificity of 91% and 90%, respectively when 
discriminating between asthma, chronic obstructive pulmonary disease and healthy control 
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patients [64]. However, the electronic nose was found to lack sensitivity when discriminating 
between severe and mild asthmatics, as shown by Dragonieri et al. in 2007 [65]. 
As well as the detection of asthma, the breath profiling by the electronic nose has also been 
shown to indicate a patient’s responsiveness to steroids with greater accuracy than FeNO or 
eosinophils [66]. This has potential for improving the treatment in the future as this is largely 
cost-effective and non-invasive, providing its introduction into clinical use after it becomes 
commercially available.. 
Ultimately, the electronic nose lacks some discriminatory power when differentiating asthma 
phenotypes, however, it may be possible to utilise it as a method for measuring and analysing 
VOCs as auxiliary asthma biomarkers, pending further refinement and commercial availability. 
In addition, this technology can aid in reducing misdiagnosis and, when coupled with FeNO, as 
shown by Montuschi et al. in 2010, can be highly specific for the detection and profiling of 
VOCs as inflammatory biomarkers [67] Thus, given further research breath profiling may be 
useful in stratification of asthma types with a high degree of specificity due to the number of 
components that comprise a breath profile. 
Exhaled breath temperature (EBT) represents another potentially useful biomarker, similar to 
exhaled breath profiling. Kumar et al. in 1998 compared blood flow in the airway mucosa of 
asthmatic patients and healthy controls utilizing a complex dimethyl ether uptake method [
68
]. 
They found that blood flow in asthmatic patients was almost twice as high (68.2 ± 7.9 µl/min·ml 
in receiving glucocorticoids and 55.4 ± 5.3 µl/min·ml not receiving glucocorticoids) as in healthy 
patients (38.5 ± 5.3 µl/min·ml).Garcia et al. last year (2013) expanded on this and similar reports 
by investigating the possibility thatthat such increase in blood flow (due to persistent 
inflammation leading to airway remodelling, including an increase in the density of the mucosal 
vascular network)  may  be measurable as an increase in the temperature of the exhaled air69]. 
They found the exhaled breath temperature (EBT) of uncontrolled asthmatic patients to be 
increased (mean of 34.9 ± 0.8°C) in comparison to that of controlled asthmatics (33.7 ± 0.8) and 
controls (33.2 ± 0.2). While it is difficult to envisage the utilization of this potential biomarker 
for clearly distinguishing between asthma phenotypes, it may be potentially utilized in the future 
for monitoring the efficacy of asthma treatment. 
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Chitinases were described in studies by Zhu et al. in 2004 [70] and Chupp et al. in 2007 [71], 
who have identified and elucidated them as important effecter molecules in airway inflammation. 
Specifically, increased serum levels of enzymatically inactive chitinase-like protein YKL-40 
represent a possible biomarker in severe childhood asthma. This biomarker has been specifically 
proposed by Konradsen et al. 2013 to be indicative of therapy resistant asthma and was shown by 
the same team to correlate with exhaled FeNO (P=0.004), blood neutrophils (P<0.001) and 
significantly, bronchial wall thickening (P=0.01) and have a negative correlation with asthma 
control (P=0.03) [72].  
Interestingly, Konradsen et al. 2013 found that children who possessed a single nucleotide 
polymorphism in the gene CHI3L1 and were resistant to therapy had the highest levels of YKL-
40, while children with this polymorphism and controlled asthma had lower levels. In children 
who did not have this polymorphism in CHI3L1, no difference was found between resistant and 
non-resistant asthma. This evidence supports the hypothesis that increased levels of YKL-40, as 
a result of the polymorphism, are indicative of severe, therapy-resistant asthma and increased 
markers of inflammation. Whether asthma therapy resistance is due to high levels of YKL-40 or 
YKL-40 is co-product of the specific asthma type is not yet clear, regardless, YKL-40 is likely a 
easily attainable biomarker for  stratification of severity in childhood asthma. The next step for 
this biomarker should be to quantify the genetic influence and variation seen in asthma severity 
and therapy resistance between the polymorphisms in the CHI3L1 gene.   
 
Conclusion and future directions 
We described several key asthma biomarkers in terms of their potential to distinguish between 
various phenotypes of this disease and guide its pharmacotherapy. Despite recent progress, many 
doctors still diagnose and treat asthma as a single disease, rather than what it currently appears to 
be: a collection of various, closely related pathologies with similar symptoms.  
These difficulties in identifying asthma phenotypes represent perhaps the prime cause of some 
resistance to asthma stratification and personalized therapy. The next step that we expect to see 
in the future is changing the current umbrella classification to sufferers of asthmatic symptoms, 
leading to individual and stratified diagnoses based on biomarkers. This will improve our 
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understanding of various phenotypes of asthma and how they can be pharmacologically targeted. 
Currently, the clinician can use sputum, periostin and perhaps FeNO signature to classify patient 
as TH2 or non-TH2, but this is mostly useful for providing prognosis for such patients (non-TH2 
patients will be more likely to be refractory to treatment), rather than guide any specific therapy. 
We have only scratched the surface of the complexity of asthma phenotypes, and at the moment 
do not have any medications that would allow us to specifically target individual subtypes. The 
current clinical utility of asthma phenotypes is therefore marginal but we expect this to change 
drastically in the near future, leading to more personalized diagnosis and tailored treatment. 
Key Issues 
• Asthma is a chronic respiratory disorder characterized by episodes of reversible airflow obstruction, 
manifesting in shortness of breath, wheezing and cough. 
• Current diagnosis of Asthma is an “umbrella term” that is employed to diagnose groups of similar 
symptoms; however, asthma is far more diverse and requires greater stratification. To date, Inhaled 
Corticosteroids (ICS) are the most common treatment for asthma. Biomarker discovery is currently looking 
to stratify asthma endotypes to enable specific drug discovery and personalize treatment. 
• Eosinophils and neutrophils are closely linked to airway inflammation and are currently measured within 
induced sputum to stratify asthma into 4 distinct cellular types; eosinophilic (raised eosinophil levels), 
neutrophilic (raised neutrophil levels), mixed granulocytic (raised neutrophils and eosinophils) and 
paucigranulocytic (normal neutrophil and eosinophil levels). Eosinophils are most closely linked to severe 
asthma and indicate the need for ICS use. 
• Periostin is a biomarker directly linked to IL-13 and IL-5 secretion and is elevated in asthmatics with 
extensive airway remodeling. Elevated periostin can be used to distinguish between TH2-high and TH2-low 
asthma and again, indicate more severe asthma subtypes for those classified as TH2-high.  
• Nitric oxide (FeNO) is a short-lived, gaseous, free radical that is present in exhaled breath. It can be 
measured using a range of devices, including an electronic nose, which has the added ability of giving a 
profile of multiple volatile organic compounds (VOC) in addition to FeNO from exhaled breath. 
Asthmatics show elevated levels of FeNO and may show variation in levels depending on the degree of 
airway inflammation. Multiple studies have found it to be inaccurate for anything more than distinguishing 
between healthy and asthmatic patients, although researchers are hopeful that it will be refined, in 
conjunction with VOCs to indicate the risk of exacerbation on a daily basis. 
• Future asthma biomarkers include exhaled breath profiling of multiple volatile organic compounds for 
more specific distinctions between asthma subtypes. Simple lipids such as Leukotriene E-4, which are 
measurable from urine and have also been found to indicate the responsiveness of a patient to leukotriene 
receptor antagonists (LTRA), when elevated. LTRA is used to reduce airway inflammation. 
• Biomarkers are also merging into genetic testing such as a polymorphism found in CHI3L1, which encodes 
for a chitin protein YKL-40. The CHI3L1 gene is hypothesised to be indicative of severe, therapy resistant, 
childhood asthma when it contains a specific single nucleotide polymorphism. 
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Table 1. Summary of asthma studies in which periostin was investigated as a potential 
stratifying biomarker. 
Study Population Design Outcome 
Woodruff et al., 
2007[16] 
42 nonsmoking 
asthmatics (who 
did not take 
inhaled or oral 
corticosteroids for 
4 wks before 
enrolment), 28 
nonsmoking 
healthy controls, 
and 16 current 
smokers without 
asthma, but with 
mild to moderate 
airflow obstruction 
(disease controls) 
12-week RCT; 
gene expression 
examined by 
microarrays and 
qPCR (from 
samples obtained 
by bronchoscopy 
with airway 
epithelial brushing 
collection) at onset 
and after 1 wk of 
treatment with 
placebo or 
fluticasone 500 µg 
BD 
POSTN gene expressed 4.4x higher in 
asthmatics than in healthy controls, 
which decreased 2.1x after fluticasone 
treatment 
Woodruff et al., 
2009[17] 
(as above) (as above) Approximately half (20 out of 44) 
asthmatic patients have a high baseline 
expression of three TH2-related genes 
(POSTN, CLCA1, and SERPINB2), 
whereas remaining asthmatics have a low 
expression. Treatment with fluticasone 
decreases the level of expression of these 
genes in the former group to the level of 
the latter group. 
Corren et al., 
2011[18] 
219 patients with 
uncontrolled 
asthma (ACQ5 
symptom-only 
version score of ≥ 
1.5) refractory to 
ICS (≥ 6 months’ 
use), and 112 
healthy controls 
Patients 
randomized to 
receive 
lebrikizumab (anti-
IL-13) 250 mg or 
placebo 
subcutaneously for 
24 wks, and 
regularly assessed 
until 32nd wk 
Lebrikizumab improves FEV1 (by 8.2 
percentage points vs. placebo, P = 0.03) 
in TH2-high, but not in TH2-low patients 
(increase by 1.6 percentage points vs. 
placebo, but with P = 0.61), which 
directly correlates with serum periostin 
levels; no alteration in asthma symptoms 
or use of rescue medication 
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Noonan et al., 
2013[19] 
212 asthmatics 
with stable asthma 
(diagnosis of 
asthma at least 12 
months before 
treatment, a 
bronchodilator 
response, and 
relative change in 
FEV1 before 
treatment < 15%)  
Patients 
randomized into 
four approximately 
equal groups: 
receiving 
lebrikizumab (125, 
250, or 500 mg) or 
placebo 
subcutaneously for 
12 wks, and 
regularly assessed 
until 20th wk 
Lebrikizumab significantly lowers 
treatment failure rates (6% failure rate 
for lebrikizumab-treated vs 27% for 
placebo-treated patients), but has no 
significant effect on FEV1 for any 
lebrikizumab dose; and the effect of its 
administration does not differ between 
high- and low-periostin patient groups 
Hanania et al., 
2013[20] 
850 patients (aged 
12-75 yrs) with 
uncontrolled 
severe persistent 
allergic asthma 
recruited for 
EXTRA study; 
data on FeNO, 
blood eosinophils 
and serum 
periostin available 
from 394, 797, and 
534 patients, 
respectively 
Post-factum 
analysis of part of 
the population of 
EXTRA study: 
patients 
randomized to 
receive 
omalizumab (anti-
IgE, dose 
dependent on 
serum total IgE 
and patient body 
weight) or placebo 
for 48 wks  
Omalizumab decreases exacerbation rate 
in periostin-high (≥ 50 ng/ml) patients by 
30% vs placebo (95% CI: 22-51%, P = 
0.07), but not in periostin-low (< 50 
ng/ml) patients (3% decrease, 95% CI: 
24.3-32%, P = 0.94); no improvement in 
symptoms and FEV1 
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Table 2. Summary of the studies investigating exhaled nitric oxide. 
Study Population  Design Outcome  
Petsky et al., 
2012[26] 
1231 participants 
(children and 
adults) completed 
a total of 9 studies 
Meta-analysis of 9 
studies (3 adult 
using sputum 
eosinophils, and 2 
adult and 4 
children using 
FeNO); 4 of them 
double, and 5 
single-blind; 
marked variability 
in defining asthma 
exacerbations 
(main outcome in 
all studies), 
although all treated 
such exacerbations 
with oral steroids  
 
Using FeNO for guiding corticosteroid 
therapy allowed a decrease in daily dose of 
this medication in adults, compared to 
control group (mean difference of -450.03 
µg, 95% CI: -676.73 to -223.34, P < 
0.0001). However, in children the same 
strategy led to an increase in daily ICS used 
(mean difference of 140.18 µg, 95% CI: 
28.94-251.42, P = 0.014. No significant 
differences in terms of exacerbations when 
FeNO was used for guiding treatment. 
Calhoun et al., 
2012[27] 
342 adults with 
mild-to-moderate 
asthma controlled 
by low-dose ICS 
RCT of 342 adults 
evenly assigned to 
three groups: 
having their ICS 
dose adjusted by 
FeNO values, 
symptom score, or 
physician 
assessment; with 
primary outcome 
of time to 
treatment failure 
No significant difference in time to 
treatment failure among three groups. For 
physician-based assessment, the failure rate 
was 22%, for FeNO-based 20%, and for 
symptom-based 15%. Hazard ratio for 
physician-based vs biomarker-based 
assessment was 1.2 (97.5% CI: 0.6-2.3) 
Hanania et al., 
2013[20] 
850 patients (aged 
12-75 yrs) with 
uncontrolled 
severe persistent 
allergic asthma 
recruited for 
EXTRA study; 
data on FeNO, 
blood eosinophils 
and serum 
periostin available 
from 394, 797, and 
534 patients, 
respectively 
Post-factum 
analysis of part of 
the population of 
EXTRA study: 
patients 
randomized to 
receive 
omalizumab (anti-
IgE, dose 
dependent on 
serum total IgE 
and patient body 
weight) or placebo 
for 48 weeks 
Treatment with omalizumab led to a 53% 
(95% CI: 37-70%, P = 0.001) decrease in 
exacerbations (vs placebo) in the high-FeNO 
(≥ 19.5 ppb) subgroup, and to an 
insignificant 16% (95% CI: -32 to 46%, P = 
0.45) decrease in exacerbations in the low-
FeNO (< 19.5 ppb) subgroup. 
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Amelink et al., 
2013[28] 
176 patients with 
adult onset asthma, 
of whom 78 had 
severe asthma and 
90 mild-to-
moderate asthma 
(according to 
Innovative 
Medicines 
Initiative 
consensus criteria) 
Cross-sectional 
observational study 
involving two 
visits; one during 
which multiple 
clinical indices 
were measured, 
and another 
specifically for 
methacholine 
challenge 
Blood neutrophil (OR 7.6, 2.9-19.8, P < 
0.01) and sputum eosinophil (OR 1.5, 1.1-
2.2, P = 0.02) counts, but also FeNO (OR 
1.5, 1.1-2.2, P = 0.02) were found to be 
associated with severe adult-onset asthma (a 
distinct asthma phenotype) 
Holguin et al., 
2013[30] 
Severe Asthma 
Research 
Programme 
subgroup in whom 
plasma levels of             
L-arginine and 
ADMA had been 
measured: 155 
patients, 49% of 
whom had severe, 
and the rest mild-
to-moderate 
asthma; mean age 
of onset was 10 
years, and duration 
22 years; 
population divided 
into late- and 
early-onset asthma 
(onset at 12 years 
or older, or lower, 
respectively) 
Cross-sectional 
study of selected 
patients from 
SARP study 
In late-onset asthma, plasma L-
arginine/ADMA ratio was lower than in 
early-onset asthma (median of 109, 95% CI: 
81-138 vs 121, 95% CI: 94-178, P = 0.02). 
L-arginine/ADMA (log) found to be 
inversely correlated to BMI in the late-onset 
asthmatic group (r = -0.4, P = 0.0006), but 
more weakly correlated in the early-onset 
group (r = -0.2, P = 0.07). 
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Table 3. Summary of the studies investigating other potential biomarkers. 
Study Biomarker Population  Design Outcome 
Cai et al., 
2007[34] 
Cysteinyl Leukotriene 
E4 as an indicator of 
response to treatment 
with montelukast. 
 
48 patients with 
mild to 
moderate 
asthma, who 
were not 
receiving a 
concomitant 
treatment with 
leukotriene 
modifiers or oral 
corticosteroids 
and not having 
experienced any 
change in their 
asthma 
parameters in 
the preceding 10 
days 
4 wk trial of 
treatment with 
leukotriene 
receptor 
antagonist 
montelukast; 
measurement of 
various clinical 
parameters at 
onset and end of 
study; patients 
classified as 
responders if: (1) 
experienced 
reduction of ≥  
20% 
in mean symptom 
score; (2) 
reduction of ≥ 
20% 
in β2-agonist 
usage; and (3) a 
mean 
improvement of 
FEV1 
of ≥ 10% from 
baseline value 
 
25 patients classified as 
responders, and 23 as non-
responders; urinary LTE4 
level was significantly 
higher in responders than in 
non-responders (224.5 ± 
34.4 vs. 175.3 ± 37.1 pg/mg 
creatinine, p < 0.05); 
patients with urinary LTE4 > 
200 pg/mg creatinine 3.5 
times more likely (95% CI: 
1.7-15.8) to respond to  
montelukast than those 
below this level  
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Sastre et al., 
2008[39] 
prostaglandin E2 as 
an indicator of 
severity in 
Eosinophilic 
Bronchitis. 
 
13 patients with 
asthma, 13 
patients with 
nonasthmatic 
eosinophilic 
bronchitis, and 
11 controls 
(nonsmokers 
with no history 
of asthma, 
allergic 
diseases, or 
chronic 
bronchitis) 
Cross-sectional 
study, which 
meeasured 
cytokine mRNA 
levels (by real 
time qPCR), 
proinflammatory 
mediators, and 
concentration of 
eicosanoids (by 
enzyme 
immunoassays) 
in induced 
sputum 
Induced sputum PGE2 
concentrations significantly 
raised in patients with 
eosinophilic bronchitis (838 
± 612 pg/ml) compared to 
asthmatic (7.54 ± 2.14 
pg/ml) and healthy subjects 
(4 ± 1.3 pg/ml); no other 
significant differences 
between asthmatic patients 
and nonasthmatic 
eosinophilic bronchitis 
patients 
 
 Fens et al., 
2011[41] 
Profiling of exhaled 
volatile organic 
compounds for 
discrimination of 
asthma with fixed 
airways obstruction 
and chronic 
obstructive 
pulmonary disease. 
 
60 asthmatic 
patients (21 with 
fixed airways 
obstruction, and 
39 with classic 
reversible 
airways 
obstruction) and 
40 COPD 
patients (GOLD 
stages II-III) 
Cross-sectional 
study involving 
sampling of 
volatile organic 
compounds 
(VOC) in exhaled 
breath using an 
electronic nose 
sensor 
Breathprints had accuracy of 
88% in distinguishing 
between fixed asthma and 
COPD (sensitivity 85%, 
specificity 90%) and 83% 
for classic asthma 
(sensitivity 91%, specificity 
90%), which was not 
affected by current smoking 
status 
Dragonieri et 
al., 2007[42] 
Profiling of exhaled 
volatile organic 
compounds for 
discrimination 
between old and 
young asthma 
sufferers. 
10 young 
patients with 
mild asthma 
(25.1 ± 5.9 yrs, 
FEV1 62.3 ± 
23.6), 10 older 
patients with 
severe asthma 
(57.3 ± 7.1 
years, FEV1 
108.3 ± 14.7), 
and matched 10 
young and 10 
older controls 
(same in 
principle as 
above) 
Electronic nose enabled 
discrimination of both 
young and old asthma 
patients from their 
respective controls, but was 
less accurate at 
distinguishing between mild 
and severe asthma patients 
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Van der Schee 
et al., 
2013[43] 
 
Volatile organic 
compound profiling 
in comparison to 
exhaled FeNO and 
eosinophils for the 
prediction of steroid 
responsiveness. 
25 patients with 
mild or 
moderate 
asthma and 20 
controls 
6 wk RCT. 
Discontinuation 
of steroid 
treatment in 
asthmatic patients 
for 28 days or 
loss of control, 
followed by 
treatment with 
oral prednisolone 
30 mg/day for 14 
days; assessment 
of various indices 
during steroid-
free period with 
aim of predicting 
future steroid 
responsiveness 
Analysis of VOC using 
electronic nose was superior 
to both FeNO and sputum 
eosinophils in predicting 
steroid responsiveness 
(AUC = 0.883 ± 0.16, P = 
0.008; 0.545 ± 0.28, 0.751; 
and 0.610 ± 0.29, 0.441, 
respectively) 
Montuschi et 
al., 2010[44] 
Volatile organic 
compopunds, FeNO 
and lung function for 
comparative 
diagnostic 
performance in 
asthma. 
27 patients with  
mild or 
moderate 
persistent 
asthma, and 24 
healthy controls 
Cross-sectional 
study which 
compared 
diagnostic 
performance of 
various 
biomarkers: 
FeNO, lung 
function testing, 
and VOC 
measured by 
electronic nose  
Diagnostic performance was 
highest for electronic nose 
(87.5%), followed by FeNO 
(79.2%) and lung function 
testing (70.8%); highest 
diagnostic performance was 
obtained by combining 
electronic nose and FeNO 
(95.8%) 
Garcia et al., 
2013[45] 
Exhaled breath 
temperature for the 
prediction of asthma 
and discrimination 
between controlled 
and uncontrolled 
asthma. 
100 patients 
with persistent 
asthma (50 with 
controlled and 
50 with 
uncontrolled) 
and 50 healthy 
controls 
Cross-sectional 
study, which 
measured lung 
function by  post-
bronchodilator 
forced 
spirometry, 
asthma control 
test and exhaled 
breath 
temperature 
(EBT) 
Patients with asthma had 
significantly increased EBT 
compared to healthy 
controls; this was 
particularly visible in 
uncontrolled asthmatics 
(EBT of 34.9 ± 0.8 ⁰C) 
compared to well-controlled 
asthmatics (EBT 33.7 ± 0.8 
⁰C) and controls (EBT 33.2 
± 0.2 ⁰C, P < 0.001) 
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Konradsen et 
al., 2013[47] 
Chitinase-3-like 
protein 1- YKL-40 
(secreted 
glycoprotein) for the 
prediction of therapy 
resistance in children 
with asthma. 
34 children with 
severe refractory 
asthma, 39 
children with 
controlled 
persistent 
asthma, and 27 
healthy controls 
Cross-sectional 
study, involving 
using ELISA to 
measure serum 
YKL-40 levels 
and other clinical 
measurements 
Children with therapy-
resistant asthma had 
significantly higher serum 
YKL-40 levels compared 
with healthy children (19.2 
ng/ml vs 13.8 ng/ml, P = 
0.03), which in these 
children correlated with 
FeNO (r = 0.48, P = 0.004), 
blood neutrophils (r = 0.63, 
P < 0.001) and bronchial 
wall thickening on high-
resolution CT (r = 0.45, P = 
0.01). 
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